Literature DB >> 10811644

Characterization of interleukin-1 receptor-associated kinase in normal and endotoxin-tolerant cells.

L Li1, S Cousart, J Hu, C E McCall.   

Abstract

Interleukin-1 receptor-associated kinase (IRAK), a signal transducer for interleukin-1, has also been suggested to participate in the Toll-like receptor-mediated innate immune response to bacterial endotoxin lipopolysaccharide (LPS). Using the human promonocytic THP-1 cell line, we demonstrated that the endogenous IRAK is quickly activated in response to bacterial LPS stimulation, as measured by its in vitro kinase activity toward myelin basic protein. LPS also triggers the association of IRAK with MyD88, the adaptor protein linking IRAK to the Toll-like receptor/interleukin-1beta receptor intracellular domain. Macrophage cells with prolonged LPS treatment become tolerant to additional dose of LPS and no longer express inflammatory cytokines. Endotoxin tolerance is a common phenomenon observed in blood from sepsis patients. We observed for the first time that the quantity of IRAK is greatly reduced in LPS-tolerant THP-1 cells, and its activity no longer responds to further LPS challenge. In addition, IRAK does not associate with MyD88 in the tolerant cells. Furthermore, application of AG126, a putative tyrosine kinase inhibitor, can substantially alleviate the LPS-induced cytokine gene expression and can also decrease IRAK level and activity. Our study indicates that IRAK is essential for LPS-mediated signaling and that cells may develop endotoxin tolerance by down-regulating IRAK.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10811644     DOI: 10.1074/jbc.M001950200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

1.  Downregulation of the DNA-binding activity of nuclear factor-kappaB p65 subunit in Porphyromonas gingivalis fimbria-induced tolerance.

Authors:  George Hajishengallis; Robert J Genco
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

Review 2.  Establishment of intestinal homeostasis during the neonatal period.

Authors:  Silvia Stockinger; Mathias W Hornef; Cécilia Chassin
Journal:  Cell Mol Life Sci       Date:  2011-09-28       Impact factor: 9.261

3.  Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling.

Authors:  Md A Nahid; Minoru Satoh; Edward K L Chan
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

4.  Low-grade inflammatory polarization of monocytes impairs wound healing.

Authors:  Ruoxi Yuan; Shuo Geng; Keqiang Chen; Na Diao; Hong Wei Chu; Liwu Li
Journal:  J Pathol       Date:  2016-01-25       Impact factor: 7.996

Review 5.  Effects of flagellin on innate and adaptive immunity.

Authors:  Anna N Honko; Steven B Mizel
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 6.  The proteasome: a central regulator of inflammation and macrophage function.

Authors:  Nilofer Qureshi; Stefanie N Vogel; Charles Van Way; Christopher J Papasian; Asaf A Qureshi; David C Morrison
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 7.  Regulations and roles of the interleukin-1 receptor associated kinases (IRAKs) in innate and adaptive immunity.

Authors:  Lu Gan; Liwu Li
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

8.  Differential regulation and role of interleukin-1 receptor associated kinase-M in innate immunity signaling.

Authors:  Jianmin Su; Qifa Xie; Ingred Wilson; Liwu Li
Journal:  Cell Signal       Date:  2007-02-22       Impact factor: 4.315

Review 9.  The involvement of the interleukin-1 receptor-associated kinases (IRAKs) in cellular signaling networks controlling inflammation.

Authors:  Lorna Ringwood; Liwu Li
Journal:  Cytokine       Date:  2008-01-30       Impact factor: 3.861

Review 10.  Mechanisms of deoxynivalenol-induced gene expression and apoptosis.

Authors:  J J Pestka
Journal:  Food Addit Contam Part A Chem Anal Control Expo Risk Assess       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.